Human immunodeficiency virus (HIV) antigens and RNA in HIV-seronegative women with cervical intraepithelial neoplasia

AIDS Research and Human Retroviruses

Volumn 25, Issue 3, 2009, Pages 249-259

  Basu, Jayasri ^a   Romney, Seymour L ^a   Angeletti, Ruth H ^a   Vermund, Sten H ^b   Nieves, Edward ^a   Kadish, Anna S ^a   Mikhail, Magdy S ^a   Orr, George A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; GAG PROTEIN; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PROSTATE SPECIFIC ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADULT; ANTIGEN RECOGNITION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN TISSUE; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS LOAD; WESTERN BLOTTING; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; VAGINA; VAGINAL LAVAGE; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HIV; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HUMANS; RNA, VIRAL; VAGINA; VAGINAL DOUCHING;

EID: 65449161020     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0096     Document Type: Article

References (40)

1. Broeckel U, Maresso K, and Kugathasan S: Functional ge-nomics and its implications for molecular medicine. Pediatr Clin North Am 2006;53:807-816.
2. Nilsson CL and Davidsson P: New separation tools for comprehensive studies of protein expression by mass spec-trometry. Mass Spectrom Rev 2000;19:390-397.
3. Burk RD, Kadish AS, Calderin S, and Romney SL: Human papillomavirus infection of the cervix detected by cervi-covaginal lavage and molecular hybridization: Correlation with biopsy results and Papanicolaou smear. Am J Obstet Gynecol 1986;154:982-989.
4. Basu J, Mikhail MS, Ahn CW, et al.: Plasma uric acid levels in women with cervical intraepithelial neoplasia. Nutr Cancer 2005;51:25-31.
5. Kadish AS, Timmins P, Wang Y, et al.: Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002;11:483-488.
6. Basu J, Romney SL, Angeletti RH, et al.: Proteomic analysis of cervicovaginal lavage samples: Identification of human immunodeficiency virus proteins. 9th International Meeting of Human Virology, Baltimore, MD, August 28, 2005.
7. Ho GY, Palan PR, Basu J, et al.: Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer 1998;78:594-599.
8. Feingold AR, Vermund SH, Burk RD, et al.: Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1990;3:896-903.
9. Vermund SH, Kelley KF, Klein RS, et al.: High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 1991; 165:392-400.
10. Klein RS, Ho GYF, Vermund SH, Fleming I, and Burk RD: Risk factors for squamous epithelial lesions on Pap smear in women at risk for human immunodeficiency virus infection. J Infect Dis 1994;170:1404-1409.
11. Ellerbrock TV, Chiasson MA, Bush TJ, et al.: Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031-1037.
12. Delmas MC, Larsen C, van Benthem B, et al.: Cervical squamous intraepithelial lesions in HIV-infected women: Prevalence, incidence and regression. European study group on natural history of HIV infection in women. AIDS 2000;14:1775-1784.
13. Petry KU, Scheffel D, Bode U, et al.: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994;57:836-840.
14. Fruchter RG, Maiman M, Sedlis A, Bartley L, Camilien L, and Arrastia CD: Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996;87:338-344.
15. Castle PE, Schiffman M, Gravitt PE, et al.: Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68:417-423.
16. Klevens RM, Fleming PL, Mays MA, and Frey R: Characteristics of women with AIDS and invasive cervical cancer. Obstet Gynecol 1996;88:269-273.
17. Iversen AKN, Larsen AR, Jensen T, et al.: Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998;177:1214-1220.
18. Hart CE, Lennox JL, Pratt-Palmore M, et al.: Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999;179:871-882.
19. Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, and Nesvizhskii A: The need for guidelines in publication of peptide and protein identification data: Working group on publication guidelines for peptides and protein identification data. Mol Cell Proteomics 2004;3:531-533.
20. Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH, et al.: Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol 2006;103:1017-1022.
21. Mervis RJ, Ahmad N, Lillehoj EP, et al.: The gag gene products of human immunodeficiency virus type 1: Align- ment within the gag open reading frame, identification of posttranslation modifications, and evidence for alternative gag precursors. J Virol 1988;62:3993-4002.
22. Veronese FD, Copeland TD, Oroszlan S, Gallo RC, and Sarngadharan MG: Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol 1988;62:795-801.
23. Rasheed S, Li Z, Xu D, and Kovacs A: Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol 1996;175:122-130.
24. Pudney J, Quayle AJ, and Anderson DJ: Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005;73:1253-1263.
25. Yeaman GR, Asin S, Weldon S, et al.: Chemokine receptor expression in the human ectocervix: Implications for infection by the human immunodeficiency virus-type I. Immunology 2004;113:524-533.
26. Prakash M, Kapembwa MS, Gotch F, and Patterson S: Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women. J Reprod Immunol 2001;52:101-111.
27. Ouellet M, Barbeau B, and Tremblay MJ: Protein tyrosyl phosphatases in T cell activation: Implication for human immunodeficiency virus transcriptional activity. Prog Nucleic Acid Res Mol Biol 2003;73:69-105.
28. Nekhai S, Jerebtsova M, Jackson A, and Southerland W: Regulation of HIV-1 transcription by protein phosphatase 1. Curr HIV Res 2007;5:3-9.
29. Patterson BK, Landay A, Andersson J, et al.: Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. Am J Pathol 1998;153:481-490.
30. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutants alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722- 725.
31. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367- 377.
32. Devito C, Hinkula J, Kaul R, et al.: Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000;14:1917-1920.
33. Trabattoni D, Caputo SL, Maffeis G, et al.: Human [alpha] defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr 2004;35:455-463.
34. Dorrell L, Hessell AJ, Wang M, et al.: Absence of specific mucosal antibody response in HIV-exposed uninfected sex workers from the Gambia. AIDS 2001;14:1117-1122.
35. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
36. Becker Y: The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals--A review, hypothesis and implications. Virus Genes 2005;31:113- 119.
37. Kunanusont C, Foy HM, Kreiss JK, et al.: HIV-1 subtypes and male to female transmission in Thailand. Lancet 1995; 345:1078-1083.
38. McNeeley TB, Shugars DC, Rosendahl M, Tucker C, Eisen-berg SP, and Wahl, SM: Inhibition of human immunodeficiency virus type I infectivity by secretory leukocyte protease inhibitor occurs prior to virus reverse transcription. Blood 1997;90:1141-1149.
39. Hall HI, Lee LM, Glynn MK, and Song DVM: Heterosexual transmission of HIV -29 states, 1999-2002. MMWR Morb Mortal Wkly Rep 2004;53:125-129.
40. Irwin KL, Pau CP, Lupo D, et al.: Presence of human immunodeficiency virus type I subtype A infection in a New York community with high prevalence. A sentinel site for monitoring HIV genetic diversity in North America. J Infect Dis 1997;176:1629-1633.